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Successful advances in the treatment of advanced malignant diseases rely on recruitment of patients into clinical trials of novel agents.
However, there is a genuine concern for the welfare of individual patients. The aim of this study was to examine motives of patients
entering early clinical trials of novel cancer therapies. Questionnaire survey with both open- and close-ended questions. The patients
were surveyed after they had given informed consent and before or during the first cycle of treatment. In all, 38 phase I/II trial patients
participated and completed the survey. Obtaining possible health benefit was listed by 89% as being a ‘very important’ factor in their
decision to participate, with only 17% giving reasons of helping future cancer patients and treatment. Other items cited as a ‘very
important’ motivating factor were ‘trust in the doctor’ (66%), ‘being treated by the latest treatment available’ (66%), ‘better standard
of care and closer follow-up’ (61%), and ‘closer monitoring of patients in trials’ (58%). Only 47% patients indicated that someone had
explained to them about any ‘reasonable’ alternatives to the trial. In total, 71% strongly agreed that ‘surviving for as long time as
possible was the most important thing (for them)’. Nearly all (97%) indicated that they knew the purpose of the trial and had enough
time to consider participation in the trial (100%). In this survey, most patients entering phase I and II clinical trials felt they understood
the purpose of the research and had given truly informed consent. Despite this, most patients participated in the hope of therapeutic
benefit, although this is known to be a rare outcome in this patient subset. Trialists should be aware, and take account of the
expectations that participants place in trial drugs.
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Successful advances in the treatment of advanced malignant
diseases are reliant on recruitment of patients into clinical trials of
novel agents (Tannock, 1995). These studies are normally
restricted to patients with advanced malignant disease that is
refractory to standard therapy. There is, however, genuine concern
with regard to the welfare of the individual patients in such clinical
trials (The National Commission, 1979; Faden et al, 1986).
Although all phases of clinical trials are associated with ethical
issues, there are particular problems with phase I and phase II
trials. Firstly, preclinical experiments provide only limited
information from which to predict the dose, schedule, toxicity,
and anticancer activity of the drug in man. Patients in phase I
trials, therefore, run the risk of receiving doses of drug that have
no biological effect or, alternatively, excessively high doses with
the risk of serious toxicity. Although phase I trials of newer agents
have the potential to minimise the risk of toxicity by using more
rational biological end points, most current trials still use the
traditional end points of toxicity for selection of the recommended
phase II dose (Parulekar and Eisenhauer, 2004). Similar risk can
also occur in phase II trials. Secondly, this is a particularly
vulnerable group of patients, who are usually well aware of their
advanced malignant disease, short life expectancy, and lack of
established treatment options. Ethically, treatment of these
patients should ensure that they are well informed about potential
risks and benefits associated with trial participation as well as the
alternatives to trial participation.
Patients’ understanding of the difference between therapeutic
and nontherapeutic research has been called into question
(Appelbaum et al, 1987; Lidz et al, 2004). The published literature
on patient motivation to participate in clinical trials suggests that
altruism may not be the sole motivating factor; self-interest is also
important (Penman et al, 1984; Rodenhuis et al, 1984; Kodish et al,
1992; Daugherty et al, 1995; Itoh et al, 1997; Yoder et al, 1997). A
recent systematic review, however, has questioned whether
participation in clinical trials is of any benefit to participants
(Peppercorn et al, 2004). Various studies have reported that the
chance of therapeutic response for those volunteering to take part
in phase I trial is less than 5% (Estey et al, 1986; Decoster et al,
1990; Von Hoff and Turner, 1991; Smith et al, 1996; Roberts et al,
2004). In phase II clinical trials, the overall objective response rate
(partial and complete) is also usually low. Higher response rates
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s(420–30%) must be observed in breast or small cell lung cancer
to make a new drug interesting for further development, as there
are numerous drugs already active in these tumour types. In
contrast, in tumour types such as glioma and melanoma where
there are few effective treatments response rates as low as 5% may
still render the drug interesting and potentially useful as a future
treatment option.
In this study, we investigated the motivations and inhibiting
factors for patients participating in phase I and phase II cancer
clinical trials, their understanding of the purpose of the research
and alternatives to trial participation, and influences on the
decision to enter the trial.
MATERIALS AND METHODS
Between January 2001 and January 2002, patients with advanced or
metastatic cancer attending the Aberdeen and North Centre for
Haematology, Oncology and Radiotherapy (ANCHOR) Unit who
had given informed consent to participate in clinical trials were
invited to take part in a questionnaire study. The local ethical
committee approved the study design and the final format of the
questionnaire. Patients were identified through the hospital’s
Medicines Assessment Research Unit (MARU) and the oncology
research nurses. The patients were approached as in-patients or
outpatients, depending on the nature of the treatment they were
receiving.
The survey’s principal investigator (PI) asked patients if they
would agree to participate in a questionnaire survey that would
take around 15–20min to complete (see Supplementary informa-
tion). Once verbal approval was obtained, the PI issued the
questionnaire before any treatment began. Assurance was given to
patients that it would not affect their treatment should they choose
not to complete the questionnaire, and that their anonymity would
be maintained. The questionnaire was completed in the absence of
the research nurses. The questionnaires were returned by mail
(stamped addressed envelope was provided where necessary) or
hand delivered to the ward or the clinic. A maximum of 1 month
was allowed for the return of the questionnaire.
Study instruments
The questionnaire was adopted from Daugherty et al (1995) with
the author’s permission, but included a new section on the ‘trade-
off’ between quality of life (QOL) and long-term survival. Prior to
commencing this study, the questionnaire was piloted with 20
patients at a similar stage of recruitment to cancer trials to ensure
clarity of meaning.
Analysis of the data was carried out using SPSS for Windows
(version 10.0.7 program). The primary statistical analysis was
intended to be descriptive in nature. Secondary analysis was
performed using nonparametric tests for independent samples
with the Mann–Whitney test for two-sided independent samples
at the 5% significance level. Accuracy of the data was checked in
100% of the cases by the second author after going through each
questionnaire and checking all the completed data input.
RESULTS
Patient accrual
In all, 104 patients were approached for the study. Of these, 63
patients were participants of phase III trials and were ineligible for
the study. Of the remaining 41 patients, 14 were participants in
phase II trials and 27 in phase I trials. We found that we had
double counted two patients who had completed the questionnaire
twice (for different trials), so we excluded their second ques-
tionnaires, and another that was largely incomplete, leaving a final
cohort of 38 participants. Tables 1 and 2 show the demographic
and general health characteristics of the participants.
Questionnaire responses
Overall 98% of the close-ended questions were answered. In all,
92% had answered the open-ended question ‘Can you tell us the
main reason that you are participating in this clinical trial?’, and
these responses were analysed for key words or phrases (hope of
remission, help me/help others, improve health, reduce tumour) to
look for clues for patient motivation. Only six (17%) gave altruistic
reasons of helping future cancer patients and treatment (‘If it can
help other cancer patients, then that’s good’), whereas 22 (58%)
gave answers indicating some hope of therapeutic response (‘To
help me get better’, ‘Had two different chemotherapies before but
didn’t have the desired effect’).
In the closed questions, 30 (82%) listed helping future cancer
patients as being a ‘very important’ motivating factor for
participating in the trial. Other important motivating items cited
were ‘possible health benefit’ (89%), ‘trust in the doctor’ (66%),
‘trust in nurses’ (76%), ‘being treated by the latest treatment
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savailable’ (66%), ‘better standard of care and closer follow-up’
(61%), ‘being likely to obtain more information about my
condition’ (58%), and ‘closer monitoring of patients in trials’
(58%).
Patient expectations
In total, 35 (92%) thought patients benefit from clinical trials and
33 (87%) rated highly the possibility of personal clinical benefit. If
offered the chance to participate in a future trial, 18 (47%)
indicated ‘probably yes’ and 16 (42%) ‘definitely yes’. Chemother-
apy-naı ¨ve patients were more likely to have positive expectations
of benefit from participating in the trial than those patients who
had previously had chemotherapy (100 vs 78%) (z¼1.91;
P¼0.05). Men were significantly more likely than women (100
vs 64%) to have positive expectations from participating in the
trials (z¼3.09; Po0.01).
QOL vs long-term survival
In the questions about QOL and length of survival, 27 (71%)
strongly agreed that ‘surviving for as long time as possible is the
most important thing’ (for them). In all, 21 (55%) strongly
disagreed that maintaining QOL was less important. A total of 23
(60%) strongly agreed that they ‘would rather maintain a better
QOL for a shorter term than suffer somewhat for longer’, with nine
(24%) neither agreeing nor disagreeing (Table 3).
Sources of information
Table 4 shows the sources of information that the patients had
used since diagnosis. In all, 29 (76%) sought more information
about their illness and treatment options after their diagnosis, 17
(45%) prior to the treatment and 19 (50%) during treatment. A
total of 12 (32%) obtained more information when looking for a
different treatment. In total, 20 (53%) had contacted relatives,
friends, and other people for more information, while the Internet
and the MacMillan or Marie Curie organisations were used by 26%.
In all, 30 (82%) had discussed their prognosis with their oncologist
and 33 (87%) said they understood their prognosis.
Comprehension
When asked through close-ended questions, 37(97%) indicated
that they gave informed consent, with 36 (95%) having understood
all or most of the trial information given to them (Table 5).
Virtually all patients said that someone had explained that the trial
was part of medical research, and told them the type of treatment
they would be getting. Patients felt they had had plenty of time to
think things over. Nearly all patients (97%) said that the side
effects they might experience and the risks involved (89%) were
explained to them. A total of 18 (47%) patients indicated that
someone had explained to them about any ‘reasonable’ alter-
natives.
Phase I trial patients were significantly more likely than patients
on phase II trials (65 vs 25%) to indicate that no ‘reasonable’
alternatives to having this treatment were explained (z¼2.287;
Po0.05). Patients who previously had chemotherapy were
significantly more likely than chemotherapy-naı ¨ve patients (70 vs
27%) to indicate that no reasonable alternatives to treatment were
explained to them (z¼2.554; Po0.01).
Table 2 Patient health status (N¼38)
Never (%) Rarely (%) Sometimes (%) Frequently (%) Always (%)
Needing help to travel about 55 13 16 3 13
Staying indoors all day due to health 53 8 24 10 5
Being in bed or chair most day 50 10 32 5 3
Not being able to do vigorous activities 32 11 5 16 34
Having trouble climbing/walking 42 11 26 18 3
Having trouble bending/lifting 42 16 24 8 10
Needing help with eating/bath 89 3 5 3
Having trouble working 34 18 32 10 5











Surviving for as long a time as possible is the MOST
IMPORTANT thing for me
71 11 11 3 3
Maintaining QOL is LESS IMPORTANT for me 8 8 10 10 55
I would rather maintain a better quality of life for a shorter
time than suffer somewhat for longer
60 11 24 5 0
QOL¼quality of life. In the grid above, there are three statements: please indicate with a tick in the appropriate column the extent to which you agree/disagree with each of the
three statements.
Table 4 Sources of information (N¼38)
Question Yes (%)
I got more information about my illness/treatment options...
Just after diagnosis 29 (76)
Before treatment 17 (45)
During treatment 19 (50)
When looking for a different treatment 12 (32)
I contacted...
The National Cancer Alliance — —
Literature (books/journals, other than hospital ones) 9 (24)
The Internet 10 (26)
Relatives, friends, other people 20 (53)
Patient support groups, for example, CLAN, BACUP 7 (18)
MacMillan or Marie Curie organisations 10 (26)
Other organisations, for example, Cancer Research Campaign 6 (16)
The hospital, outside my appointment times 5 (13)
Were you satisfied with the amount of information received? 29 (76)
Has a doctor ever spoken with you about your prognosis? 31 (82)
Do you think that you understand what your prognosis is? 33 (87)
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Most (97%) when asked through close-ended questions made up
their own mind to participate in the trial, although doctors at the
cancer centre, family, and family doctors (to a lesser extent) were
also influential (Table 6). In all, 20 (52%) found the decision to
participate in the trial ‘easy’. In total, 31 (82%) made the decision
to participate completely on their own and seven (18%) partially.
DISCUSSION
We found that most participants felt they were well informed and
that their decisions about trial participation were made indepen-
dently. The main area of concern was that only half of the patients
felt that they had ‘reasonable’ alternatives to trial participation
explained. Those not aware of ‘reasonable’ alternative treatment
were, however, predominantly participants in phase I trials, where
the only alternative was likely to have been an alternative
experimental therapy or best supportive care.
Our study has some limitations – in particular, it is a small study
from a single institution – but the participants are likely to be
broadly representative of those in phase I and II clinical trials. On
direct questioning, the two main motivational factors for trial
participation were possible health benefit and helping future
cancer patients. The differences we found in responses to open-
and close-ended questions suggest, however, that participants’
main motivation was personal health gain. Whereas phrasing of a
closed question might influence the response, open-ended ques-
tion may more freely elicit patients’ true feelings. For example, Cox
(2003) found that QOL of patients in phase I and phase II cancer
drug trials as measured by closed question instruments was
unaffected by trial participation, whereas qualitative data from in-
depth interviews demonstrated considerable physical and psycho-
logical impact from experimental chemotherapy. Our finding that
personal health benefit was the most important motivation and
expectation for most patients is in line with previous findings
(Daugherty et al, 1995; Yoder et al, 1997; Cheng et al, 2000). How
then do we explain this apparent mismatch in a group of patients
who report being well informed?
Patients may have interpreted the information they received
optimistically. Cox (2002) reported that patients interpreted the
wording of information sheets optimistically, for example, the
words ‘study’, ‘new’, or ‘American’ treatment were taken to mean
‘better’ than conventional treatments. The positive presentation of
trials was reinforced by faith patients place in the decision of their
consultants to offer this treatment. Our results with regard to trust
in doctors are similar to those obtained by Penman et al (1984)
and Daugherty et al (1995). This vulnerable group of patients may
be at risk of pressure by their doctors to enter studies, but we
found few who did not decide independently to participate.
Albrecht et al (1999) found that patients were more likely to
consent to the trial when their physician verbally presented items
normally included in an informed consent document and when
they behaved in a ‘reflective, patient-centred, supportive, and
responsive manner’.
Cheng et al (2000) found that participants in phase I clinical
have high expectations regarding the success of experimental
therapy and discount potential toxicity, and that patients perceive
potential benefits and toxicities differently than health-care
professionals. We observed similar findings in that most patients
rated highly the possibility of personal benefit. Slevin et al (1990)
found that patients with cancer are willing to accept treatment with
cytotoxics for lower chances of benefit than those thought
acceptable by their physicians or nurses.
Many patients maintain hope and optimism despite advanced
cancer. In a qualitative study, we found that many patients needed
to maintain some degree of hope (Bain et al, 2002) and others have
reported the same (Leydon et al, 2000). For a patient whose illness
has progressed on standard therapy and for whom no other
established therapy is available, a less than 5% chance of
therapeutic benefit could be regarded as reasonable justification
for study entry. Furthermore, with increased use of targeted
therapy, the risk of toxic effects experienced by participants in
phase I trials is improving (Roberts et al, 2004).
Patients are attracted to a clinical trial by ‘being treated by a
doctor with a specialist interest in the disease and encouraged by
the possibility that their progress will be monitored closely’ (Slevin
et al, 1995). High-quality care and closer monitoring are realistic
expectations for phase I and phase II trials. Patients in these trials
have a dedicated team of nurses, pharmacists, and doctors looking
after them and have close contact with the oncology department.




The type of treatment you would get 38 (100)
The purpose of this treatment 37 (97)
Unintended side effects you may experience 37 (97)
Risks involved in having this treatment 34 (89)
Benefits you may experience in having this treatment 34 (89)
That this trial was part of medical research 38
Any reasonable alternatives to having this treatment 18 (47)
Do you think you were well informed? 37 (97)
Were you able to ask enough questions? 36 (95)
Did you understand all of the trial information 18 (47)
Did you understand most of the trial information 18 (47)
Did you understand some of the trial information 2 (6)
Did you understand almost none of the trial information 0 —
Additionally did you understand...
How the research trial would achieve this 34 (89)
How the trial worked 33 (87)
How the trial could help patients now 34 (89)
How the trial could help future cancer patients 33 (87)
The possible benefits and risks to patients in the trial 34 (89)
That you are free to withdraw from the trial at any point in time 37 (97)
That the trial is ethically approved and regulated 34 (89)
Did you give informed consent 37 (97)
Did you have enough time to consider 38 (100)
Did you know the purpose of this trial 37 (97)
Table 6 Patients’ decision-making and influences for participation in the
trial (N¼38)
Yes (%)
Did you make up your own mind to participate in this trial? 37 (97)
With whom did you discuss your decision...
Doctors at the cancer centre 31 (82)
Nurses 6 (16)






Or somewhat in between? 12 (32)
Would you say you made your own decision...
Completely 31 (82)
Partially 7 (18)
Or almost not all? —
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sThis provides continuity of care, prompt attention to symptom
control, and a high level of support.
Our findings confirm that when patients believe they are well
informed, their understanding of potential risks (predominantly to
QOL) and benefits (mostly in terms of the small potential for
benefit to survival) are key to their decisions to participate in
phase I and phase II clinical trials. In an attempt to illuminate this
further, we asked questions on the trade offs they would make
between survival and QOL. Their responses demonstrate the
importance they placed on both survival and QOL, but their trade
offs were inconsistent with each other (most strongly agreed that
survival for as long as possible was most important, and also that
QOL was more important than survival). Instead, their responses
appear to be in line with the way statements were framed,
suggesting that patients’ consideration of risks and benefits, even
when fully understood, is vulnerable to manipulation (Thornton,
2003).
Overall, we have found that nearly all patients recruited to phase
I and II clinical trials felt they were fully informed about the
research and, with the possible exception of alternative treatments,
appeared to be well informed on direct questioning. Despite this,
most took part primarily in the hope of therapeutic benefit. Trialist
clinicians should take account of patients’ potential misconcep-
tions about early clinical trials of anticancer agents during
recruitment, and should ensure clarity and an honest approach
to such vulnerable patients.
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